These bacteria hide themselves and then take charge

January 11, 2023

These bacteria hide themselves and then take chargeA doctor discovers bacteria in a sample that is causing a case of pneumonia and prescribes antibiotics. Some so-called multi-drug-resistant bacteria can even survive several types of antibiotics. – We found that those who fell ill could have other, multi-drug-resistant variants of the same bacterium “hiding” in their body. – There is a higher risk of serious illness in children if they are infected by multi-drug-resistant bacteria before they are vaccinated. Corander adds that in Norway, we are lucky in that the incidence of multi-drug-resistant bacteria is currently low.

These bacteria hide themselves and then take charge

A doctor discovers bacteria in a sample that is causing a case of pneumonia and prescribes antibiotics. But at the same time, there is another, nastier variant of bacteria lurking in the patient’s body that is very glad to have got rid of its competitor. 

Gerry Tonkin-Hill, a postdoctoral fellow at the Institute for Basic Medical Sciences, and collaborators checked 4000 blood samples for many different variants of the bacterium Streptococcus pneumoniae.

All over the world, there is an increasing problem of antibiotics not working when treating certain bacteria. Some so-called multi-drug-resistant bacteria can even survive several types of antibiotics. 

– The bacterium Streptococcus pneumoniae can cause pneumonia, meningitis and bacteraemia. Many different variants of this bacterium exist and our study reveals that you can have several variants in your body at the same time, explains Gerry Tonkin-Hill, a postdoctoral fellow at the Institute for Basic Medical Sciences at the University of Oslo.

The researchers went looking for variants that are multi-drug-resistant. These bacteria can pose a larger risk to children and the elderly, causing serious illness and even death.

– We found that those who fell ill could have other, multi-drug-resistant variants of the same bacterium “hiding” in their body. When the patient begins taking antibiotics to combat the first bacterium, the other multi-drug-resistant variant can then take over, since it no longer has to compete against the first one, explains Tonkin-Hill.

The study was recently published in Nature Microbiology

A deeper analysis of samples from patients is important

Tonkin-Hill and his collaborators recruited mothers and children in Thailand and took blood samples from them every month for a period of two years. The researchers then selected 4000 samples that they checked for many different variants of the bacterium using a new method, based on what is termed deep sequencing. The study is likely the largest to use this method up until now.

The researchers recorded how many of the participants fell ill during the two-year period and what sort of antibiotic treatment they received. They also found that the bacterium was often transmitted from mother to child and vice versa.

– Most people have this bacterium in their body without getting ill. But if, for instance, a virus infection takes hold, pneumococci can subsequently result in a serious bacterial infection, says the postdoctoral fellow.

Every year, 300,000 children throughout the world die due to illness caused by the pneumococcus bacterium. Tonkin-Hill says the study‘s findings will play an important role when it comes to developing good methods of treatment for the future. One improvement will be to carry out a deeper analysis of patient samples.

– There is a higher risk of serious illness in children if they are infected by multi-drug-resistant bacteria before they are vaccinated. Since our study has shown that several variants can be present in the body at the same time, it may be necessary to consider more carefully which antibiotic to use and to monitor the child further after treatment has been given, he believes.

In addition, Tonkin-Hill advocates better monitoring so that any spread of the most harmful bacteria is quickly contained.

Vaccination cannot solve all the challenges posed by pneumonia and multi-drug-resistance

Professor Jukka Corander at the Department of Biostatistics. (Photo: Mona Mehus, UiO)

Tonkin-Hill’s supervisor, professor Jukka Corander at the Department of Biostatistics, says that vaccines against pneumonia are not a full-proof solution to this problem.

– We currently have a vaccine to combat 13 types of these bacteria and new vaccines are in the pipeline which should protect against 20 others. But over 100 types already exist. They develop fast, which means that there are ever new variants that can result in serious illness, he says. 

We need rapid tests for diagnosis and treatments that are better tailored to the individual patient

According to the professor, there are two things that are especially important if we are to win the battle against these bacteria.

– One is that we must find quicker ways of making a diagnosis and of analysing blood samples in greater detail in order to find all the variants that are present in the patient’s blood. At present, it can take between one to three days to get an answer on the resistance factors relating to a bacterium. In the future, I hope that rapid diagnosis will be the norm. Work is being carried out on this in several places, for example at Haukeland Hospital in Bergen. The aim is to be able to get an answer within one to three hours.

The other aspect that Corander believes to be important is the ability to tailor treatments more in the future. This means carefully checking which variant of the bacterium is making the patient ill and administering a narrow-spectrum medicine that has been developed to combat that very variant. 

– Several pilot projects for this are underway, for instance at Oslo University Hospital, Rikshospitalet and Ullevål, he reveals.

Corander adds that in Norway, we are lucky in that the incidence of multi-drug-resistant bacteria is currently low. But we must continually strive to prevent multi-drug-resistance becoming a growing threat in the future, he says. 

The study was a collaboration between a FRIPRO project at the University of Oslo, the Wellcome Sanger Institute, Oxford University, the Shoklo Malaria Research Unit and Imperial College London.

For more information:

Pneumococcal within-host diversity during colonization, transmission and treatment
 

The source of this news is from University of Oslo

Popular in Research

1

2 days ago

Paper-thin solar cell can turn any surface into a power source

2

Jan 13, 2023

Study Reveals the Intrinsic Immune Mechanism that Boosts Axon Regeneration in the Adult Nervous System

3

Jan 14, 2023

ASCERTAIN: New Horizon Europe research project to improve the affordability and sustainability of innovative health technologies

4

Jan 21, 2023

Financy and UniSA partnership delivers tech platform to take diversity, equity and inclusion measurement to the next level

5

Jan 25, 2023

A healthy wind

Biden says ‘no’ to US sending F-16 fighter jets to Ukraine

8 hours ago

NYU Production Lab Announces Three New Slate Film Projects

1 day ago

Tesla stock suffers worst week since 2020 as Elon Musk sells, large shareholder asks for new CEO

6 hours ago

In Debt Limit Fight, Republicans Won’t Say What Spending Cuts They Want

8 hours ago

Reframing the first-generation academic experience

1 day ago

UNSW community recognised with Australia Day honours

1 day ago